menu
    • menu

    Company profile for Beacon Therapeutics

    NEW Drugs in Dev: 9
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Beacon Therapeutics is an ophthalmic gene therapy company founded in 2023 to restore and improve the vision of patients with a range of prevalent and rare retinal diseases that result in blindness. The Company has an established scientific foundation that combines a late-stage development candidate to treat X-linked retinitis pigmentosa (XLRP) with two preclinical programs, one targeting dry age-related macular degeneration (A...
    Beacon Therapeutics is an ophthalmic gene therapy company founded in 2023 to restore and improve the vision of patients with a range of prevalent and rare retinal diseases that result in blindness. The Company has an established scientific foundation that combines a late-stage development candidate to treat X-linked retinitis pigmentosa (XLRP) with two preclinical programs, one targeting dry age-related macular degeneration (AMD) and another in-licensed from the University of Oxford targeting cone-rod dystrophy (CRD). Lead development candidate AGTC-501, is a gene therapy program in Phase II clinical trials for the treatment of XLRP.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Beacon Therapeuticsunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    Rolling Stock Yard, 2nd floor 188 York Way Kings Cross London, N7 9AS
    Telephone
    Telephone
    +44 (0)203 3987880
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.beacontx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/beacon-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Beacon Therapeutics Presents at 44th JPM Healthcare Conference
    Beacon Therapeutics Presents at 44th JPM Healthcare Conference

    18 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/18/3207646/30580/en/Beacon-Therapeutics-to-Present-at-the-44th-Annual-JP-Morgan-Healthcare-Conference.html

    GLOBENEWSWIRE
    18 Dec 2025
    Share Share
    Beacon Therapeutics Initiates First Patient In Laru-Zova Trial
    Beacon Therapeutics Initiates First Patient In Laru-Zova Trial

    16 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/16/3206165/30580/en/Beacon-Therapeutics-Treats-First-Patient-in-LANDSCAPE-Trial-of-laru-zova-in-Patients-with-X-linked-Retinitis-Pigmentosa-XLRP.html

    GLOBENEWSWIRE
    16 Dec 2025
    Share Share
    Beacon Therapeutics Joins Jefferies Global Healthcare Conference
    Beacon Therapeutics Joins Jefferies Global Healthcare Conference

    12 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/12/3186150/30580/en/Beacon-Therapeutics-to-Participate-in-the-Jefferies-Global-Healthcare-Conference.html

    GLOBENEWSWIRE
    12 Nov 2025
    Share Share
    Beacon Pharma Joins Chardan's Genetic Medicines Conference
    Beacon Pharma Joins Chardan's Genetic Medicines Conference

    15 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/15/3167016/30580/en/Beacon-Therapeutics-to-Participate-in-Chardan-s-9th-Annual-Genetic-Medicines-Conference.html

    GLOBENEWSWIRE
    15 Oct 2025
    Share Share
    Beacon Therapeutics Joins Bank of America Healthcare Conference
    Beacon Therapeutics Joins Bank of America Healthcare Conference

    10 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/10/3147700/30580/en/Beacon-Therapeutics-to-Participate-in-the-2025-Bank-of-America-Healthcare-Trailblazers-Private-Company-Conference.html

    GLOBENEWSWIRE
    10 Sep 2025
    Share Share
    Beacon Reveals 9+ Month DAWN & 36-Month SKYLINE Trial Results
    Beacon Reveals 9+ Month DAWN & 36-Month SKYLINE Trial Results

    04 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/04/3144423/30580/en/Beacon-Therapeutics-Announces-Positive-Interim-9-Month-Results-from-DAWN-Trial-and-36-Month-Phase-2-SKYLINE-Trial-Data-for-Laru-zova-in-Patients-with-X-linked-Retinitis-Pigmentosa-.html

    GLOBENEWSWIRE
    04 Sep 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search